Research studies from Indonesia are grabbing the attention of stakeholders in the platelet rich plasma market. Due to the increasing number of COVID-19 cases in Indonesia, autologous activated platelet-rich plasma (aaPRP) has been gaining recognition for potentials in suppressing cytokine release syndrome (CRS) in patients. Since cytokine storm has been a typical symptom among coronavirus patients in Indonesia, intravenous autologous activated platelet-rich plasma holds promising potentials to reduce death rates.
Postponement and rescheduling of medical treatments have affected revenue flow in the platelet rich plasma market during the ongoing pandemic. Nevertheless, companies are implementing comprehensive vendor reviews to ensure robust medical supplies at healthcare facilities. They are reviewing processes for monitoring expiration dates and replace old supplies with new ones.
The platelet rich plasma market is expected to reach the valuation of US$ 815.3 Mn by 2031. Although the equipment used to produce PRP and the injections have been cleared by the FDA (Food and Drug Administration), this procedure is considered investigational and has not been officially approved by the FDA for many uses. Nevertheless, PRP is a low-risk procedure and linked with minor side effects.
Outside of the orthopedic treatment, PRP is being used for the treatment of hair loss, for skin rejuvenation, and post-surgical healing. Healthcare companies are establishing stable revenue streams with the help of PRP injections meant for tendon, muscle, and join injuries.
The platelet rich plasma market is slated to clock a robust CAGR of 11.2% during the forecast period. The American Society of Plastic Surgeons has been witnessing a significant increase in the use of cosmetic PRP in the past few years. This is evident, as treatments using PRP show great promise for harnessing the body’s own natural tissue repair processes to help patients achieve improved form and function.
Platelet rich plasma is being prepared by manufacturers in the platelet rich plasma market with the help of various methods such as centrifugation, which involves spinning a small sample of the patient’s blood into separate components, followed by other steps. The growing popularity of vampire facial consisting of non-surgical microneedling followed by topical application of PRP is creating revenue opportunities for market stakeholders.
Since PRP mimics the body’s natural healing process, companies in the platelet rich plasma market are tapping incremental opportunities in orthopedics. Increased levels of platelets lead to increased growth factors, which have the potential to improve signaling and recruitment of cells to promote quicker & efficient healing in complex orthopedic conditions in patients.
AOA Orthopedic Specialists has been gaining recognition for increasing the availability of PRP in order to either delay or prevent an orthopedic surgery or to use in conjunction with the surgery.
Analysts’ Viewpoint
As pharmaceutical and life sciences companies make changes to supply chains, stakeholders in the platelet rich plasma market are revisiting key assumptions in financial projections, owing to potential supply chain disruptions. PRP is gaining prominence in plastic surgery. However, for cosmetic procedures, the treatment can be potentially time consuming and may require multiple session, leading to high costs. Hence, stakeholders should increase awareness about the advantages of cosmetic PRP that shows dramatic improvements in skin contour. As such, PRP is being deployed for orthopedic conditions such as knee arthritis and promote healing after an orthopedic surgery. Companies in the platelet rich plasma market are enhancing their production capabilities to produce PRP for treatment of chronic tendon injuries, acute ligament injuries and fractures amongst others.
|
Attribute |
Detail |
|
Market Size Value in 2020 (Base Year) |
US$ 275.1 Mn |
|
Market Forecast Value in 2031 |
US$ 893.3 Mn |
|
Growth Rate (CAGR) |
11.2% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porters Five Forces analysis, supply chain analysis, parent industry overview, etc. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global platelet rich plasma market was worth US$ 275.1 Mn in 2020 and is projected to reach a value of US$ 815.3 Mn by the end of 2031
Platelet rich plasma market is anticipated to grow at a CAGR of 11.2% during the forecast period
North America accounted for a major share of the global platelet rich plasma market
Platelet rich plasma market is driven by rise in prevalence of various orthopedic diseases, and surge in demand for effective hair-loss treatment are the key factors projected to propel the global market during the forecast period
Key players in the global platelet rich plasma market include Zimmer Biomet, AdiStem Ltd., ISTO Biologics, ThermoGenesis Holdings, Inc., Stryker Corporation, Exactech, Inc., EmCyte Corporation, Regen Lab, Arthrex, Inc., TERUMO BCT, INC. (Terumo Corporation), DePuy Synthes Companies (Johnson & Johnson), Celling Biosciences, Inc., and Juventix Regenerative Medical, LLC.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Platelet Rich Plasma Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Platelet Rich Plasma Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Pricing Analysis
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Platelet Rich Plasma Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Pure-PRP
6.3.2. Leukocyte-rich PRP
6.3.3. Pure-PRF
6.4. Market Attractiveness Analysis, by Type
7. Global Platelet Rich Plasma Market Analysis and Forecast, by Origin
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Origin, 2017–2031
7.3.1. Autologous
7.3.2. Allogeneic
7.3.3. Homologous
7.4. Market Attractiveness Analysis, by Origin
8. Global Platelet Rich Plasma Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Orthopedic Surgery
8.3.2. Cosmetic Surgery
8.3.3. General Surgery
8.3.4. Neurosurgery
8.3.5. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Platelet Rich Plasma Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Global Platelet Rich Plasma Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Pure-PRP
10.2.2. Leukocyte-rich PRP
10.2.3. Pure-PRF
10.3. Market Value Forecast, by Origin, 2017–2031
10.3.1. Autologous
10.3.2. Allogeneic
10.3.3. Homologous
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Orthopedic Surgery
10.4.2. Cosmetic Surgery
10.4.3. General Surgery
10.4.4. Neurosurgery
10.4.5. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Origin
10.6.3. By Application
10.6.4. By Country
11. Europe Global Platelet Rich Plasma Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Pure-PRP
11.2.2. Leukocyte-rich PRP
11.2.3. Pure-PRF
11.3. Market Value Forecast, by Origin, 2017–2031
11.3.1. Autologous
11.3.2. Allogeneic
11.3.3. Homologous
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Orthopedic Surgery
11.4.2. Cosmetic Surgery
11.4.3. General Surgery
11.4.4. Neurosurgery
11.4.5. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Origin
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Global Platelet Rich Plasma Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Pure-PRP
12.2.2. Leukocyte-rich PRP
12.2.3. Pure-PRF
12.3. Market Value Forecast, by Origin, 2017–2031
12.3.1. Autologous
12.3.2. Allogeneic
12.3.3. Homologous
12.4. Market Value Forecast By Application, 2017–2031
12.4.1. Orthopedic Surgery
12.4.2. Cosmetic Surgery
12.4.3. General Surgery
12.4.4. Neurosurgery
12.4.5. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Origin
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Latin America Global Platelet Rich Plasma Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Pure-PRP
13.2.2. Leukocyte-rich PRP
13.2.3. Pure-PRF
13.3. Market Value Forecast, by Origin, 2017–2031
13.3.1. Autologous
13.3.2. Allogeneic
13.3.3. Homologous
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Orthopedic Surgery
13.4.2. Cosmetic Surgery
13.4.3. General Surgery
13.4.4. Neurosurgery
13.4.5. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Origin
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Middle East & Africa Global Platelet Rich Plasma Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Pure-PRP
14.2.2. Leukocyte-rich PRP
14.2.3. Pure-PRF
14.3. Market Value Forecast, by Origin, 2017–2031
14.3.1. Autologous
14.3.2. Allogeneic
14.3.3. Homologous
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Orthopedic Surgery
14.4.2. Cosmetic Surgery
14.4.3. General Surgery
14.4.4. Neurosurgery
14.4.5. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Origin
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Zimmer Biomet Holdings, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. AdiStem Ltd.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. ISTO Biologics
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. ThermoGenesis Holdings, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Stryker Corporation
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Exactech, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. EmCyte Corporation
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. Regen Lab
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. Arthrex, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. TERUMO BCT, INC. (Terumo Corporation)
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis
15.2.11. DePuy Synthes Companies (Johnson & Johnson)
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis
15.2.12. APEX Biologix, LLC
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Strategic Overview
15.2.12.5. SWOT Analysis
List of Tables
Table 01: Global Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Origin, 2017-2031
Table 03: Global Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 06: North America Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 07: North America Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Origin, 2017-2031
Table 08: North America Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 09: Europe Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 11: Europe Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Origin, 2017-2031
Table 12: Europe Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 13: Asia Pacific Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 15: Asia Pacific Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Origin, 2017-2031
Table 16: Asia Pacific Platelet Rich Plasma Market Value (US$ Mn) Forecast, by Application, 2017-2031
List of Figures
Figure 01: Global Platelet Rich Plasma Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Platelet Rich Plasma Market Value Share, by Type, 2020
Figure 03: Global Platelet Rich Plasma Market Value Share, by Origin, 2020
Figure 04: Global Platelet Rich Plasma Market Value Share, by Application, 2020
Figure 05: Global Platelet Rich Plasma Market Value Share, by Region, 2020
Figure 06: Global Platelet Rich Plasma Market Value (US$ Mn), by Pure-PRF, 2017-2031
Figure 07: Global Platelet Rich Plasma Market Value Share Analysis, by Type, 2020 and 2031
Figure 08: Global Platelet Rich Plasma Market Value (US$ Mn), by Pure-PRP, 2017–2031
Figure 09: Global Platelet Rich Plasma Market Value (US$ Mn), by Pure-PRF, 2017–2031
Figure 10: Global Platelet Rich Plasma Market Attractiveness Analysis, by Type, 2021–2031
Figure 11: Global Platelet Rich Plasma Market Value Share Analysis, by Type, 2020 and 2031
Figure 12: Global Platelet Rich Plasma Market Value (US$ Mn), by Autologous 2017–2031
Figure 13: Global Platelet Rich Plasma Market Value (US$ Mn), by Allogeneic, 2017–2031
Figure 14: Global Platelet Rich Plasma Market Value (US$ Mn), by Pure-PRF, 2017–2031
Figure 15: Global Platelet Rich Plasma Market Attractiveness Analysis, by Origin, 2021–2031
Figure 16: Global Platelet Rich Plasma Market Value Share Analysis, by Type, 2020 and 2031
Figure 17: Global Platelet Rich Plasma Market Value (US$ Mn), by Orthopedic Surgery, 2017–2031
Figure 18: Global Platelet Rich Plasma Market Value (US$ Mn), by Cosmetic Surgery, 2017–2031
Figure 19: Global Platelet Rich Plasma Market Value (US$ Mn), by General Surgery, 2017–2031
Figure 20: Global Platelet Rich Plasma Market Value (US$ Mn), by Neurosurgery, 2017–2031
Figure 21: Global Platelet Rich Plasma Market Value (US$ Mn), by Others, 2017–2031
Figure 23: Global Platelet Rich Plasma Market Value Share Analysis, by Region, 2020 and 2031
Figure 24: Global Platelet Rich Plasma Market Attractiveness Analysis, by Region, 2021–2031
Figure 25: North America Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 26: North America Platelet Rich Plasma Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 27: North America Platelet Rich Plasma Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 28: North America Platelet Rich Plasma Market Value Share (%), by Type, 2020 and 2031
Figure 29: North America Platelet Rich Plasma Market Attractiveness, by Type, 2021–2031
Figure 30: North America Platelet Rich Plasma Market Value Share (%), by Origin, 2020 and 2031
Figure 31: North America Platelet Rich Plasma Market Attractiveness, by Origin, 2021–2031
Figure 32: North America Platelet Rich Plasma Market Value Share (%), by Application, 2020 and 2031
Figure 33: North America Platelet Rich Plasma Market Attractiveness Analysis, by Application, 2021–2031
Figure 34: Europe Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 35: Europe Platelet Rich Plasma Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 36: Europe Platelet Rich Plasma Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 37: Europe Platelet Rich Plasma Market Value Share (%), by Type, 2020 and 2031
Figure 38: Europe Platelet Rich Plasma Market Attractiveness, by Type, 2021–2031
Figure 39: Europe Platelet Rich Plasma Market Value Share (%), by Origin, 2020 and 2031
Figure 40: Europe Platelet Rich Plasma Market Attractiveness, by Origin, 2021–2031
Figure 41: Europe Platelet Rich Plasma Market Value Share (%), by Application, 2020 and 2031
Figure 42: Europe Platelet Rich Plasma Market Attractiveness Analysis, by Application, 2021–2031
Figure 43: Asia Pacific Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 44: Asia Pacific Platelet Rich Plasma Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 45: Asia Pacific Platelet Rich Plasma Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Asia Pacific Platelet Rich Plasma Market Value Share (%), by Type, 2020 and 2031
Figure 47: Asia Pacific Platelet Rich Plasma Market Attractiveness, by Type, 2021–2031
Figure 48: Asia Pacific Platelet Rich Plasma Market Value Share (%), by Origin, 2020 and 2031
Figure 49: Asia Pacific Platelet Rich Plasma Market Attractiveness, by Origin, 2021–2031
Figure 50: Asia Pacific Platelet Rich Plasma Market Value Share (%), by Application, 2020 and 2031
Figure 51: Asia Pacific Platelet Rich Plasma Market Attractiveness Analysis, by Application, 2021–2031
Figure 52: Latin America Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 53: Latin America Platelet Rich Plasma Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 54: Latin America Platelet Rich Plasma Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 55: Latin America Platelet Rich Plasma Market Value Share (%), by Type, 2020 and 2031
Figure 56: Latin America Platelet Rich Plasma Market Attractiveness, by Type, 2021–2031
Figure 57: Latin America Platelet Rich Plasma Market Value Share (%), by Origin, 2020 and 2031
Figure 58: Latin America Platelet Rich Plasma Market Attractiveness, by Origin, 2021–2031
Figure 59: Latin America Platelet Rich Plasma Market Value Share (%), by Application, 2020 and 2031
Figure 60: Latin America Platelet Rich Plasma Market Attractiveness Analysis, by Application, 2021–2031
Figure 61: Middle East and Africa Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 62: Middle East and Africa Platelet Rich Plasma Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 63: Middle East and Africa Platelet Rich Plasma Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 64: Middle East and Africa Platelet Rich Plasma Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 65: Middle East and Africa Platelet Rich Plasma Market Value Share (%), by Type, 2020 and 2031
Figure 66: Middle East and Africa Platelet Rich Plasma Market Attractiveness, by Type, 2021–2031
Figure 67: Middle East and Africa Platelet Rich Plasma Market Value Share (%), by Origin, 2020 and 2031
Figure 68: Middle East and Africa Platelet Rich Plasma Market Attractiveness, by Origin, 2021–2031
Figure 69: Middle East and Africa Platelet Rich Plasma Market Value Share (%), by Application, 2020 and 2031
Figure 70: Middle East and Africa Platelet Rich Plasma Market Attractiveness Analysis, by Application, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Platelet Rich Plasma Market Forecast Report, 2021-2031
